This site is intended for health professionals only

Published on 16 October 2008

Share this story:
Twitter
LinkedIn

Specialists’ high hopes for Avastin

teaser

A survey of cancer specialists has revealed that of the many targeted cancer agents in phase III clinical trials, Avastin is the most promising to treat early-stage colorectal cancer.

In excess of half of those surveyed said an 18% in overall improvement in survival rates would be the minimum benefit that would persuade them to prescribe Avastin for early-stage colorectal cancer.

The four drugs they currently favour are Herceptin, Sutent, Nexavar and Tykerb, although they would add new drug Avastin once it has gained regulatory approval for early-stage cancers.

Nearly all surveyed oncologists prescribe Herceptin, Tykerb, Sutent and Nexavar for their approved indications in cancer, such as breast cancer, non-small-cell lung cancer and renal cell carcinoma.

The Physician & Payer Forum report said there is evidence that patients who are not helped by Herceptin should switch to Tykerb and the National Cancer Institute says those who find Sutent does not work could benefit from Nexavar.

Copyright © PA Business 2008

Decision Resources



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn